Developer docs
API playgroundTry for free, no card

Search company profiles

EFFIK

Full company profile

uuid000bvd3

Namestring
EFFIK
Legal namestring
EFFIK SA
Websiteurl
effik.fr
Company typeenum
Private
Founded yearint
1992
Descriptiontext

EFFIK is a French pharmaceutical laboratory founded in 1992 and headquartered in Meudon, operating as the wholly-owned French subsidiary of the Italian ITALFARMACO group (acquired in 2015). The company employs 110+ collaborators and specializes primarily in women's health, with a diversified portfolio spanning prescription medications (contraceptives, menopause therapies, anti-infectives, anti-nausea treatments for pregnancy), CE-marked Class IIa medical devices (vaginal gels, muco-adhesive ovules, connected pelvic floor electrostimulators), dietary supplements (the NATALBEN preconception/pregnancy/postpartum range using Quatrefolic 5-MTHF), and cosmetics. Since 2016 EFFIK has expanded beyond its women's health core into neurology via TEGLUTIK (riluzole) for ALS, and in 2023 established a dedicated rare diseases team focused on Duchenne Myopathy. The company's technology base includes proprietary pharmaceutical formulations (e.g., Quatrefolic 5-MTHF, fenticonazole-based antifungals), Class IIa medical devices with novel mechanism architectures (Geliofil Protect, Polybactum), and a connected electrostimulation device (GynEffik Connect) controlled via a smartphone application. EFFIK operates a B2B go-to-market model distributing exclusively through French pharmaceutical wholesale distributors (grossistes répartiteurs), hospital/healthcare establishments (établissements de santé), and pharmacies (pharmacies d'officine), supported by a field sales force of certified medical representatives (Délégués médicaux) and an integrated call center for order support and medical information. Revenue is generated through one-time sales of prescription drugs, medical devices, and dietary supplements at prices determined by the French pharmaceutical distribution system, with no public pricing disclosed. Customer segments span the full women's health lifecycle (contraception, fertility, pregnancy, postpartum, menopause, intimate comfort), healthcare professionals (gynecologists, midwives, GPs, pharmacists), institutional buyers (hospitals, wholesalers), and — more recently — neurology and rare disease patient populations.

Short descriptiontext

EFFIK is a French pharmaceutical laboratory founded in 1992 and owned by ITALFARMACO, specializing in women's health (contraception, fertility, pregnancy, menopause, intimate comfort) with recent expansion into neurology and rare diseases, distributing its prescription medications, medical devices, and dietary supplements through French pharmacies, hospitals, and wholesalers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersMeudon, France
HQ citystring
Meudon
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
women's health pharmaceuticals, hormonal contraceptives, gynecological medical devices, dietary supplements fertility, menopause hormone therapy
Industry2 codes
PRIMARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYCRADAGAK
Women’s Health Supplements (Prenatal, Menopause, Hormonal)
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Surgical Appliance and Supplies Manufacturing339113
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Women's Health Pharmaceuticals
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Prescription Pharmaceuticals
TypeOne Time License
Description

EFFIK develops and distributes prescription medicines including hormonal contraceptives (TRIAFEMI, CARLIN, DESOBEL, DROSPIBEL, FÉMI), menopause treatments (ESTIMA, BLISSEL), anti-infectives (LOMEXIN, TERLOMEXIN, BEAGYNE), neurological treatments (TEGLUTIK/Riluzole for ALS), and nausea treatments (CARIBAN). Revenue is generated through wholesale and pharmacy distribution.

effik.fr
2Medical Devices
TypeOne Time License
Description

Class IIa medical devices including vaginal gels (Geliofil Protect), intimate comfort products (AINARA), pelvic floor electrostimulators (GYNEFFIK 2.0, Gyneffik Connect), and vaginal ovules (Polybactum). Distributed through pharmacies and healthcare channels.

effik.fr
3Dietary Supplements
TypeOne Time License
Description

Nutritional supplements for preconception, pregnancy, postpartum, and fertility (NATALBEN range: Préconception, Grossesse, Grossesse ORO, Mama; ANDROMAS for male fertility; OVUNOL for female fertility; FERTIFOL). Sold through pharmacies.

effik.fr
4Cosmetics
TypeOne Time License
Description

Cosmetic products including Zelesse intimate care wash, distributed through pharmacy channels.

effik.fr
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Supply Chain, Marketing or Sales, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1NATALBEN
Description

Range of nutritional supplements for preconception, pregnancy, and postpartum (NATALBEN Préconception, Grossesse, Mama, Grossesse ORO).

effik.fr
+4 more records
Core offering1 text field

EFFIK is a French pharmaceutical laboratory that develops, manufactures, and distributes prescription medicines, medical devices, and dietary supplements primarily for women's health. Its portfolio covers contraception (oral pills), fertility and preconception supplementation, pregnancy support, menopause management, infectious diseases (antifungals, bacterial vaginosis), and intimate comfort products, plus an ALS neurology franchise and rare-disease initiatives through its ITALFARMACO parent group.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 94/100 on the Gender Equality Index (Index Égalité Femmes/Hommes) for 2025
+1 more record
Product overview1 text field

EFFIK is a French pharmaceutical laboratory founded in 1992 specializing in women's health, with operations since 2016 expanding into neurology. The company offers a diversified portfolio spanning medications, dietary supplements, and medical devices. In gynecology, the portfolio includes: contraceptive medications (TRIAFEMI, TRIAFEMI Continu, DROSPIBEL, DESOBEL, CARLIN, FEMI); fertility products (ANDROMAS and OVUNOL dietary supplements); pregnancy/postpartum supplements (NATALBEN Preconception, NATALBEN Grossesse, NATALBEN Grossesse ORO, NATALBEN Mama, plus CARIBAN medication and FERTIFOL); menopause treatments (ESTIMA capsules and BLISSEL vaginal gel); infectious disease products (LOMEXIN cream/capsules, TERLOMEXIN, BEAGYNE, GELIOFIL Protect, POLYBACTUM medical devices); and intimate comfort products (AINARA vaginal gel, ZELESSE intimate wash). In therapeutic products, EFFIK offers GYNEFFIK 2.0 and GYNEFFIK Connect pelvic floor electrostimulators for urinary incontinence, NATECAL calcium/vitamin D supplements, and TEGLUTIK for ALS treatment. The company operates as a unified product portfolio rather than a platform architecture, serving gynecologists, pharmacists, midwives, and patients through pharmaceutical, supplement, and medical device channels.

Product and service26 records
1TRIAFEMI contraceptive range
CategoryPrescription Contraceptives
Description

Triphasic oral contraceptive pill containing Norgestimate/Ethinylestradiol, also available in a continuous-use version, prescribed by gynecologists and dispensed through pharmacies.

2DROSPIBEL contraceptive range
CategoryPrescription Contraceptives
Description

Monophasic oral contraceptive pills containing Ethinylestradiol/Drospirenone available in two estrogen doses, prescribed for contraception through pharmacies.

3DESOBEL contraceptive range
CategoryPrescription Contraceptives
Description

Monophasic oral contraceptive pills containing Desogestrel/Ethinylestradiol available in two progestin doses for women's contraception.

4CARLIN contraceptive range
CategoryPrescription Contraceptives
Description

Monophasic oral contraceptive pills containing Gestodene/Ethinylestradiol available in two progestin doses for women's contraception.

5FÉMI contraceptive pill
CategoryPrescription Contraceptives
Description

Monophasic oral contraceptive pill containing Norgestimate/Ethinylestradiol, prescribed for women seeking hormonal contraception.

6ANDROMAS dietary supplement
CategoryFertility Dietary Supplements
Description

Powder dietary supplement for male fertility containing myo-inositol, Quatrefolic 5-MTHF, vitamin D, selenium, zinc, and coenzyme Q10.

7OVUNOL dietary supplement
CategoryFertility Dietary Supplements
Description

Powder dietary supplement for female fertility containing myo-inositol, Quatrefolic 5-MTHF, iodine, selenium, vitamin D, and zinc.

8NATALBEN Preconception
CategoryPregnancy Dietary Supplements
Description

Dietary supplement for preconception containing Quatrefolic 5-MTHF, vitamin B12, zinc, and iodine to support reproductive health.

9NATALBEN Grossesse
CategoryPregnancy Dietary Supplements
Description

Dietary supplement for pregnancy containing omega-3, vitamins, minerals, and lutein to support fetal development and maternal well-being.

10NATALBEN Grossesse ORO
CategoryPregnancy Dietary Supplements
Description

Vegan-certified orodispersible pregnancy supplement in powder form that dissolves in the mouth without water.

11NATALBEN Mama
CategoryPregnancy Dietary Supplements
Description

Postpartum and breastfeeding dietary supplement containing omega-3, vitamins, minerals, lutein, and taurine for maternal recovery and infant development.

12CARIBAN 10 mg/10 mg
CategoryPrescription Medicines
Description

Modified-release prescription capsule containing doxylamine succinate/pyridoxine hydrochloride for treating nausea and vomiting during pregnancy.

13FERTIFOL 400 µg
CategoryPrescription Medicines
Description

Folic acid supplement tablet for preconception and pregnancy used to prevent neural tube defects.

14ESTIMA progesterone capsules
CategoryMenopause Hormone Therapy
Description

Progesterone soft capsules available in 100 mg and 200 mg doses for oral or vaginal administration in menopausal hormone therapy.

15BLISSEL 50 µg/g vaginal gel
CategoryMenopause Hormone Therapy
Description

Vaginal gel containing estriol for treating vulvovaginal atrophy symptoms in menopausal women.

16LOMEXIN antifungal range
CategoryAntifungal Medicines
Description

Fenticonazole nitrate in soft vaginal capsule (600 mg) and vaginal cream (2%) formulations for treating fungal vaginal infections.

17TERLOMEXIN 200 mg
CategoryAntifungal Medicines
Description

Vaginal soft capsule containing fenticonazole nitrate (200 mg) for treatment of vaginal candidiasis.

18GELIOFIL Protect vaginal gel
CategoryMedical Devices
Description

Class IIa CE-marked vaginal gel medical device with triple action (protective barrier, symptom relief, flora restoration) for treating bacterial vaginosis using lactic acid and lactobacillus-friendly pH.

19POLYBACTUM vaginal ovule
CategoryMedical Devices
Description

Class IIa CE-marked vaginal ovule medical device with polycarbophile and lauryl glucoside providing a bacteriostatic barrier against Gardnerella Vaginalis to prevent bacterial vaginosis recurrence.

20BEAGYNE 150 mg
CategoryAntifungal Medicines
Description

Prescription capsule containing fluconazole (150 mg) for treatment of vaginal fungal infections.

21AINARA vaginal gel
CategoryIntimate Comfort Medical Devices
Description

Class IIa CE-marked non-hormonal vaginal gel with dual moisturizing and lubricating action for vulvovaginal atrophy and dryness relief.

22ZELESSE intimate wash
CategoryIntimate Comfort Cosmetics
Description

Cosmetic intimate wash lotion enriched with Burdock extract, Aloe vera, and Chamomile for daily intimate hygiene and relief of vulvovaginitis symptoms.

23TEGLUTIK 5 mg/ml
CategoryNeurology Prescription Medicines
Description

Oral suspension containing riluzole (5 mg/ml) for treatment of Amyotrophic Lateral Sclerosis (ALS), launched in 2016 as part of EFFIK's neurology franchise.

24GYNEFFIK pelvic floor electrostimulators
CategoryMedical Devices
Description

Class IIa CE-marked pelvic floor electrostimulator devices (wired GYNEFFIK 2.0 and smartphone-connected GYNEFFIK Connect) for home rehabilitation of female urinary incontinence, including stress, urge, and mixed forms.

25NATECAL VITAMINE D3 600 mg/400 IU
CategoryMineral Supplements
Description

Orodispersible tablet containing calcium and cholecalciferol (vitamin D3) for mineral supplementation.

26ETHINYLOESTRADIOL EFFIK 50 µg
CategoryPrescription Hormone Therapy
Description

Oral tablet containing ethinylestradiol (50 µg) for hormonal therapy.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Since 2022, EFFIK supports ARSLA through training projects for healthcare teams and solidarity events including the Course des Héros and Défie la SLA races. EFFIK is committed to improving the care pathway for ALS patients and their caregivers through ongoing partnerships with patient associations and healthcare professionals.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2015-01-01
Description

ITALFARMACO is the parent group of EFFIK. EFFIK joined the ITALFARMACO group in 2015. ITALFARMACO develops, manufactures, and commercializes pharmaceutical products across more than 60 countries with over 3,100 employees globally and annual revenue of €759M. The group invests more than 10% of revenue in R&D and has a portfolio of 50+ specialties spanning Women's Health, Analgesia, Cardiovascular, CNS, Dermatology, Digestive, Locomotor, Oncology, Respiratory, and Oral Hygiene. EFFIK operates as the French subsidiary of the Italian group.

3Eco-organismes (Ecosystem, Adelphe, Cyclamed)
Strategic tierMinorTypeOthers
Description

EFFIK is a member of eco-organisms for pharmaceutical packaging recycling: Ecosystem (household packaging), Adelphe (additional packaging), and Cyclamed (unused medicines). This supports EFFIK's environmental commitment to responsible product end-of-life management.

effik.fr
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeRegional player
Description

French-headquartered pharmaceutical and dermo-cosmetics company with a diversified portfolio including women's health and intimate care OTC. Comparable on French-market presence and category overlap but broader and more diversified than EFFIK's specialist focus.

TypeEmerging player
Description

IBSA is a Swiss specialty pharma with women's-health offerings in fertility and gynecology. Comparable on therapeutic areas but smaller and with different geographic emphasis — relevant emerging peer in the women's-health specialty space.

3Sandoz
TypeBroad incumbent
Description

Sandoz, the Novartis generics and biosimilars spin-off, distributes women's-health products including oral contraceptives and HRT across Europe. Comparable on product categories and channel presence, but positioned as a broad incumbent rather than a focused women's-health specialist.

4Laboratoires IPRAD
TypeDirect peer
Description

French specialty pharmaceutical laboratory with overlapping women's-health portfolio including contraception, menopause, and intimate health. Direct French-market competitor with similar scale, channel, and HCP-targeting approach.

TypeDirect peer
Description

Theramex is a specialty women's-health pharmaceutical company (contraception, HRT, fertility) headquartered in Monaco with strong French market presence. Closest direct comparable to EFFIK in therapeutic focus, channel model, and French/European footprint.

TypeBroad incumbent
Description

Bayer operates a substantial women's-health franchise spanning oral contraceptives (Yaz, Yasmin), IUDs (Mirena), and HRT. Comparable on product categories but vastly larger, broader, and global — a broad incumbent rather than direct specialist peer.

TypeBroad incumbent
Description

Organon was spun off from Merck in 2021 as a global women's-health pure-play across contraception, fertility, HRT, and biosimilars. Operates in many of the same therapeutic categories as EFFIK but with significantly greater geographic reach and resources.

TypeDirect peer
Description

Besins Healthcare is a privately-held specialty pharma focused on hormone replacement therapy, reproductive medicine, and women's health. Directly comparable to EFFIK on HRT/menopause franchise and European market focus.

TypeDirect peer
Description

Hungarian-headquartered specialty pharma with a sizable women's-health franchise including oral contraceptives, HRT, and fertility products. Comparable to EFFIK on contraceptive and women's-health product mix, though larger and more geographically diversified.

TypeDirect peer
Description

Exeltis is the women's-health specialty division of Chemo Group, focused on contraception, fertility, pregnancy, and menopause across 40+ countries. Closely comparable mid-sized specialty player targeting the same prescribers and patient populations as EFFIK.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

EFFIK

Women's Health Pharmaceuticalseffik.fr

EFFIK is a French pharmaceutical laboratory founded in 1992 and owned by ITALFARMACO, specializing in women's health (contraception, fertility, pregnancy, menopause, intimate comfort) with recent expansion into neurology and rare diseases, distributing its prescription medications, medical devices, and dietary supplements through French pharmacies, hospitals, and wholesalers.

What EFFIK does

EFFIK is a French pharmaceutical laboratory founded in 1992 and headquartered in Meudon, operating as the wholly-owned French subsidiary of the Italian ITALFARMACO group (acquired in 2015). The company employs 110+ collaborators and specializes primarily in women's health, with a diversified portfolio spanning prescription medications (contraceptives, menopause therapies, anti-infectives, anti-nausea treatments for pregnancy), CE-marked Class IIa medical devices (vaginal gels, muco-adhesive ovules, connected pelvic floor electrostimulators), dietary supplements (the NATALBEN preconception/pregnancy/postpartum range using Quatrefolic 5-MTHF), and cosmetics. Since 2016 EFFIK has expanded beyond its women's health core into neurology via TEGLUTIK (riluzole) for ALS, and in 2023 established a dedicated rare diseases team focused on Duchenne Myopathy. The company's technology base includes proprietary pharmaceutical formulations (e.g., Quatrefolic 5-MTHF, fenticonazole-based antifungals), Class IIa medical devices with novel mechanism architectures (Geliofil Protect, Polybactum), and a connected electrostimulation device (GynEffik Connect) controlled via a smartphone application. EFFIK operates a B2B go-to-market model distributing exclusively through French pharmaceutical wholesale distributors (grossistes répartiteurs), hospital/healthcare establishments (établissements de santé), and pharmacies (pharmacies d'officine), supported by a field sales force of certified medical representatives (Délégués médicaux) and an integrated call center for order support and medical information. Revenue is generated through one-time sales of prescription drugs, medical devices, and dietary supplements at prices determined by the French pharmaceutical distribution system, with no public pricing disclosed. Customer segments span the full women's health lifecycle (contraception, fertility, pregnancy, postpartum, menopause, intimate comfort), healthcare professionals (gynecologists, midwives, GPs, pharmacists), institutional buyers (hospitals, wholesalers), and — more recently — neurology and rare disease patient populations.

EFFIK firmographics

Firmographics
Name
EFFIK
Legal name
EFFIK SA
Website
https://effik.fr
Company type
Private
Founded year
1992
Operating status
Operating
Headcount range
101–250 employees
Short description
EFFIK is a French pharmaceutical laboratory founded in 1992 and owned by ITALFARMACO, specializing in women's health (contraception, fertility, pregnancy, menopause, intimate comfort) with recent expansion into neurology and rare diseases, distributing its prescription medications, medical devices, and dietary supplements through French pharmacies, hospitals, and wholesalers.
Ownership category
akta.pro rank

EFFIK industry classification

Industry
Product category
Women's Health Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Surgical Appliance and Supplies Manufacturing (339113), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYCRADAGAK
Women’s Health Supplements (Prenatal, Menopause, Hormonal)

Keywords

  • Women's health pharmaceuticals
  • Hormonal contraceptives
  • Gynecological medical devices
  • Dietary supplements fertility
  • Menopause hormone therapy

Where EFFIK is headquartered

Location

Headquarters

HQ city
Meudon
HQ country
France
HQ region
Europe

Offices1 record

Markets served

EFFIK business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Marketing or Sales, Technology or R&D, Operations

Revenue model

  1. Prescription Pharmaceuticals: EFFIK develops and distributes prescription medicines including hormonal contraceptives (TRIAFEMI, CARLIN, DESOBEL, DROSPIBEL, FÉMI), menopause treatments (ESTIMA, BLISSEL), anti-infectives (LOMEXIN, TERLOMEXIN, BEAGYNE), neurological treatments (TEGLUTIK/Riluzole for ALS), and nausea treatments (CARIBAN). Revenue is generated through wholesale and pharmacy distribution.
  2. Medical Devices: Class IIa medical devices including vaginal gels (Geliofil Protect), intimate comfort products (AINARA), pelvic floor electrostimulators (GYNEFFIK 2.0, Gyneffik Connect), and vaginal ovules (Polybactum). Distributed through pharmacies and healthcare channels.
  3. Dietary Supplements: Nutritional supplements for preconception, pregnancy, postpartum, and fertility (NATALBEN range: Préconception, Grossesse, Grossesse ORO, Mama; ANDROMAS for male fertility; OVUNOL for female fertility; FERTIFOL). Sold through pharmacies.
  4. Cosmetics: Cosmetic products including Zelesse intimate care wash, distributed through pharmacy channels.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

EFFIK product offering

Product offering

Core offering

EFFIK is a French pharmaceutical laboratory that develops, manufactures, and distributes prescription medicines, medical devices, and dietary supplements primarily for women's health. Its portfolio covers contraception (oral pills), fertility and preconception supplementation, pregnancy support, menopause management, infectious diseases (antifungals, bacterial vaginosis), and intimate comfort products, plus an ALS neurology franchise and rare-disease initiatives through its ITALFARMACO parent group.

Product overview

EFFIK is a French pharmaceutical laboratory founded in 1992 specializing in women's health, with operations since 2016 expanding into neurology. The company offers a diversified portfolio spanning medications, dietary supplements, and medical devices. In gynecology, the portfolio includes: contraceptive medications (TRIAFEMI, TRIAFEMI Continu, DROSPIBEL, DESOBEL, CARLIN, FEMI); fertility products (ANDROMAS and OVUNOL dietary supplements); pregnancy/postpartum supplements (NATALBEN Preconception, NATALBEN Grossesse, NATALBEN Grossesse ORO, NATALBEN Mama, plus CARIBAN medication and FERTIFOL); menopause treatments (ESTIMA capsules and BLISSEL vaginal gel); infectious disease products (LOMEXIN cream/capsules, TERLOMEXIN, BEAGYNE, GELIOFIL Protect, POLYBACTUM medical devices); and intimate comfort products (AINARA vaginal gel, ZELESSE intimate wash). In therapeutic products, EFFIK offers GYNEFFIK 2.0 and GYNEFFIK Connect pelvic floor electrostimulators for urinary incontinence, NATECAL calcium/vitamin D supplements, and TEGLUTIK for ALS treatment. The company operates as a unified product portfolio rather than a platform architecture, serving gynecologists, pharmacists, midwives, and patients through pharmaceutical, supplement, and medical device channels.

Differentiator

Problem solved

Functional benefit

Brands

  • NATALBEN: Range of nutritional supplements for preconception, pregnancy, and postpartum (NATALBEN Préconception, Grossesse, Mama, Grossesse ORO).
  • GynEffik
  • Gyna
  • AINARA
  • Zelesse

Products and services

  • TRIAFEMI contraceptive range Triphasic oral contraceptive pill containing Norgestimate/Ethinylestradiol, also available in a continuous-use version, prescribed by gynecologists and dispensed through pharmacies.
  • DROSPIBEL contraceptive range Monophasic oral contraceptive pills containing Ethinylestradiol/Drospirenone available in two estrogen doses, prescribed for contraception through pharmacies.
  • DESOBEL contraceptive range Monophasic oral contraceptive pills containing Desogestrel/Ethinylestradiol available in two progestin doses for women's contraception.
  • CARLIN contraceptive range Monophasic oral contraceptive pills containing Gestodene/Ethinylestradiol available in two progestin doses for women's contraception.
  • FÉMI contraceptive pill Monophasic oral contraceptive pill containing Norgestimate/Ethinylestradiol, prescribed for women seeking hormonal contraception.
  • ANDROMAS dietary supplement Powder dietary supplement for male fertility containing myo-inositol, Quatrefolic 5-MTHF, vitamin D, selenium, zinc, and coenzyme Q10.
  • OVUNOL dietary supplement Powder dietary supplement for female fertility containing myo-inositol, Quatrefolic 5-MTHF, iodine, selenium, vitamin D, and zinc.
  • NATALBEN Preconception Dietary supplement for preconception containing Quatrefolic 5-MTHF, vitamin B12, zinc, and iodine to support reproductive health.
  • NATALBEN Grossesse Dietary supplement for pregnancy containing omega-3, vitamins, minerals, and lutein to support fetal development and maternal well-being.
  • NATALBEN Grossesse ORO Vegan-certified orodispersible pregnancy supplement in powder form that dissolves in the mouth without water.
  • NATALBEN Mama Postpartum and breastfeeding dietary supplement containing omega-3, vitamins, minerals, lutein, and taurine for maternal recovery and infant development.
  • CARIBAN 10 mg/10 mg Modified-release prescription capsule containing doxylamine succinate/pyridoxine hydrochloride for treating nausea and vomiting during pregnancy.
  • FERTIFOL 400 µg Folic acid supplement tablet for preconception and pregnancy used to prevent neural tube defects.
  • ESTIMA progesterone capsules Progesterone soft capsules available in 100 mg and 200 mg doses for oral or vaginal administration in menopausal hormone therapy.
  • BLISSEL 50 µg/g vaginal gel Vaginal gel containing estriol for treating vulvovaginal atrophy symptoms in menopausal women.
  • LOMEXIN antifungal range Fenticonazole nitrate in soft vaginal capsule (600 mg) and vaginal cream (2%) formulations for treating fungal vaginal infections.
  • TERLOMEXIN 200 mg Vaginal soft capsule containing fenticonazole nitrate (200 mg) for treatment of vaginal candidiasis.
  • GELIOFIL Protect vaginal gel Class IIa CE-marked vaginal gel medical device with triple action (protective barrier, symptom relief, flora restoration) for treating bacterial vaginosis using lactic acid and lactobacillus-friendly pH.
  • POLYBACTUM vaginal ovule Class IIa CE-marked vaginal ovule medical device with polycarbophile and lauryl glucoside providing a bacteriostatic barrier against Gardnerella Vaginalis to prevent bacterial vaginosis recurrence.
  • BEAGYNE 150 mg Prescription capsule containing fluconazole (150 mg) for treatment of vaginal fungal infections.
  • AINARA vaginal gel Class IIa CE-marked non-hormonal vaginal gel with dual moisturizing and lubricating action for vulvovaginal atrophy and dryness relief.
  • ZELESSE intimate wash Cosmetic intimate wash lotion enriched with Burdock extract, Aloe vera, and Chamomile for daily intimate hygiene and relief of vulvovaginitis symptoms.
  • TEGLUTIK 5 mg/ml Oral suspension containing riluzole (5 mg/ml) for treatment of Amyotrophic Lateral Sclerosis (ALS), launched in 2016 as part of EFFIK's neurology franchise.
  • GYNEFFIK pelvic floor electrostimulators Class IIa CE-marked pelvic floor electrostimulator devices (wired GYNEFFIK 2.0 and smartphone-connected GYNEFFIK Connect) for home rehabilitation of female urinary incontinence, including stress, urge, and mixed forms.
  • NATECAL VITAMINE D3 600 mg/400 IU Orodispersible tablet containing calcium and cholecalciferol (vitamin D3) for mineral supplementation.
  • ETHINYLOESTRADIOL EFFIK 50 µg Oral tablet containing ethinylestradiol (50 µg) for hormonal therapy.

Quantifiable outcome

  • 94/100 on the Gender Equality Index (Index Égalité Femmes/Hommes) for 2025
  • +1 more outcomes

Companies that use EFFIK

Customer profile

Named customers6 records

Segments5 records

Ideal customer profiles5 records

EFFIK technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

EFFIK partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered flagship, core and minor.

  • ARSLA (Association pour la Recherche sur la Sclérose Latérale Amyotrophique)flagshipStrategic or Co-development Partner · 1 January 2022Since 2022, EFFIK supports ARSLA through training projects for healthcare teams and solidarity events including the Course des Héros and Défie la SLA races. EFFIK is committed to improving the care pathway for ALS patients and their caregivers through ongoing partnerships with patient associations and healthcare professionals.
  • ITALFARMACO GroupcoreStrategic or Co-development Partner · 1 January 2015ITALFARMACO is the parent group of EFFIK. EFFIK joined the ITALFARMACO group in 2015. ITALFARMACO develops, manufactures, and commercializes pharmaceutical products across more than 60 countries with over 3,100 employees globally and annual revenue of €759M. The group invests more than 10% of revenue in R&D and has a portfolio of 50+ specialties spanning Women's Health, Analgesia, Cardiovascular, CNS, Dermatology, Digestive, Locomotor, Oncology, Respiratory, and Oral Hygiene. EFFIK operates as the French subsidiary of the Italian group.
  • Eco-organismes (Ecosystem, Adelphe, Cyclamed)minorOthersEFFIK is a member of eco-organisms for pharmaceutical packaging recycling: Ecosystem (household packaging), Adelphe (additional packaging), and Cyclamed (unused medicines). This supports EFFIK's environmental commitment to responsible product end-of-life management.

Scale indicators10 records

Recent moves7 records

Expansion highlights5 records

EFFIK competitors and assessment

Company assessment

Regional players

  • Pierre Fabre: French-headquartered pharmaceutical and dermo-cosmetics company with a diversified portfolio including women's health and intimate care OTC. Comparable on French-market presence and category overlap but broader and more diversified than EFFIK's specialist focus.

Emerging players

  • IBSA Pharma: IBSA is a Swiss specialty pharma with women's-health offerings in fertility and gynecology. Comparable on therapeutic areas but smaller and with different geographic emphasis — relevant emerging peer in the women's-health specialty space.

Broad incumbents

  • Sandoz: Sandoz, the Novartis generics and biosimilars spin-off, distributes women's-health products including oral contraceptives and HRT across Europe. Comparable on product categories and channel presence, but positioned as a broad incumbent rather than a focused women's-health specialist.
  • Bayer Pharmaceuticals: Bayer operates a substantial women's-health franchise spanning oral contraceptives (Yaz, Yasmin), IUDs (Mirena), and HRT. Comparable on product categories but vastly larger, broader, and global — a broad incumbent rather than direct specialist peer.
  • Organon: Organon was spun off from Merck in 2021 as a global women's-health pure-play across contraception, fertility, HRT, and biosimilars. Operates in many of the same therapeutic categories as EFFIK but with significantly greater geographic reach and resources.

Direct peers

  • Laboratoires IPRAD: French specialty pharmaceutical laboratory with overlapping women's-health portfolio including contraception, menopause, and intimate health. Direct French-market competitor with similar scale, channel, and HCP-targeting approach.
  • Theramex: Theramex is a specialty women's-health pharmaceutical company (contraception, HRT, fertility) headquartered in Monaco with strong French market presence. Closest direct comparable to EFFIK in therapeutic focus, channel model, and French/European footprint.
  • Besins Healthcare: Besins Healthcare is a privately-held specialty pharma focused on hormone replacement therapy, reproductive medicine, and women's health. Directly comparable to EFFIK on HRT/menopause franchise and European market focus.
  • Gedeon Richter: Hungarian-headquartered specialty pharma with a sizable women's-health franchise including oral contraceptives, HRT, and fertility products. Comparable to EFFIK on contraceptive and women's-health product mix, though larger and more geographically diversified.
  • Exeltis: Exeltis is the women's-health specialty division of Chemo Group, focused on contraception, fertility, pregnancy, and menopause across 40+ countries. Closely comparable mid-sized specialty player targeting the same prescribers and patient populations as EFFIK.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

EFFIK financial estimates

Financial estimate

Revenue estimate

Valuation estimate

EFFIK leadership team

Management profile

Number of profiles

Profiles7 records

EFFIK subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

EFFIK funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

EFFIK M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EFFIK

What does EFFIK do?

EFFIK is a French pharmaceutical laboratory that develops, manufactures, and distributes prescription medicines, medical devices, and dietary supplements primarily for women's health. Its portfolio covers contraception (oral pills), fertility and preconception supplementation, pregnancy support, menopause management, infectious diseases (antifungals, bacterial vaginosis), and intimate comfort products, plus an ALS neurology franchise and rare-disease initiatives through its ITALFARMACO parent group.

Is EFFIK a public or private company?

EFFIK is a private company. It is classified as corporate owned and is currently operating.

When was EFFIK founded?

EFFIK was founded in 1992. It employs 101 to 250 people.

Where is EFFIK based?

EFFIK is headquartered in Meudon, France, in the Europe region.

How does EFFIK make money?

Four revenue lines are on record. Prescription Pharmaceuticals are the primary driver. The others are medical Devices, dietary Supplements and cosmetics.

Who are EFFIK's main competitors?

Pierre Fabre is listed as a regional player. IBSA Pharma is listed as an emerging player. Broad incumbents are Sandoz, Bayer Pharmaceuticals and Organon. Direct peers are Laboratoires IPRAD, Theramex, Besins Healthcare, Gedeon Richter and Exeltis.

Does EFFIK have an API?

No public API is recorded for EFFIK.

What industry is EFFIK in?

EFFIK's product category is Women's Health Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health), with a secondary code of CRADAGAK, Women’s Health Supplements (Prenatal, Menopause, Hormonal). Its NAICS code is 325412 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales